Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
NCT00458705
Completed
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with doxorubicin hydrochloride liposome and dexamethasone follow... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/16/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
NCT01827722
Unknown
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema. Previous studies have shown that inflammatory mediators and growth factors, such as vascular endothelial growth factor (VEGF), are elevated in patients with macular edema associated with CRVO. Ozurdex® is approved by the Food and Drug Administration (FDA) and is available by prescription for m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2015
Locations: Retina Vitreous Associates Medical Group, Beverly Hills, California +4 locations
Conditions: Macular Edema, Central Retinal Vein Occlusion
Register for Updates
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00693433
Completed
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with dex... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2015
Locations: Veteran's Administration Medical Center, Las Angeles, California
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT01421173
Completed
The goal of this clinical research study is to find the highest tolerable dose of vorinostat that can be given with gemcitabine, busulfan, and melphalan with a stem cell transplant. Researchers also want to learn about the safety and level of effectiveness of this combination. Busulfan and melphalan are designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die. Gemcitabine is designed to disrupt the growth of cancer cells, which may ca... Read More
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
11/17/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
NCT00402766
Completed
Primary Objective: * To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma. Secondary Objectives: * To explore the biologic effects of cisplatin, imatinib mesylate, and pemetrexed on tumor tissue by: * histologic analysis of biopsy tissue * by non-invasive assessments of tumor vascularity performed before, during and after treatment * electron microscopy analysis of endothelial cell architecture after pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Mesothelioma
Register for Updates
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
NCT02036424
Completed
To determine if there is visual benefit with Ozurdex treatment every three months compared to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema. The investigator hypothesizes more frequent administration of Ozurdex in patients that have persistent diabetic macular edema will result in a more rapid and sustained improvement of visual acuity and/or optical coherence topography (OCT) compared to the use of anti-VEGF alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2015
Locations: Raj K Maturi MD PC, Indianapolis, Indiana
Conditions: Diabetic Macular Edema
Register for Updates
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
NCT01009931
Terminated
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2015
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Leukemia
Register for Updates
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084
Withdrawn
In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD is a combination of cyclophosphamide, mesna, vincristine (vincristine sulfate), doxorubicin (doxorubicin hydrochloride), dexamethasone, methotr... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/29/2015
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
NCT00083551
Completed
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/21/2015
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
NCT00475085
Completed
RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea. It is not yet known which combination of antiemetic drugs is more effective in preventing nausea caused by chemotherapy. PURPOSE: This randomized phase III trial is comparing different combinations of granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron to see how well they work in preventing nausea in patients undergoing chemo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2015
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +15 locations
Conditions: Nausea
Register for Updates
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
NCT00479089
Terminated
Primary Objective: 1. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone. For the purposes of this protocol, "consolidation" therapy refers to treatment given at the time of maximal benefit from conventional front-line multi-agent chemotherapy. Secondary Objective: 1. To compare time to progression (TTP), overall survival (OS) and cause-specific survival (CSS)... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/08/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Bladder Cancer
Register for Updates
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01485835
Completed
The purpose of this study is to find out what effects, good and/or bad, that ganetespib and bortezomib has on you and your cancer. The investigators will determine the side effects of different dose levels of ganetespib when given alone and the effect it has on your cancer alone. The investigators will also determine the side effects of ganetespib at different dose levels when given in combination with bortezomib and the effect the combination has on your cancer. The study will measure levels of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2015
Locations: Colorado Blood Cancer Institute, Denver, Colorado +7 locations
Conditions: Multiple Myeloma
Register for Updates